Related Experiment Videos
[Recent studies on anti-angiogenesis in cancer therapy]
Abstract:
Angiogenesis is known to be a critical process for the tumor growth and metastasis. There are many indigenous role-players in tumor angiogenesis and anti-angiogenesis, where tumor-host interaction may work. A lot of agents with anti-angiogenic activity have been developed for anti-cancer treatment. Several agents including Marimastat, Primostat, Neovastat, Bay-12-9566m, Interferon-alpha, SU101, retinoids, and IM862, are/were under phase-three study. There are still many future-promising results of basic or clinical studies on inhibitors of MMPs, and inhibitors of VEGF/R, Endostatin, somatostatin analogues, COX-2 inhibitors, and others. Most of the combination treatments of antiangiogenetic agent and conventional anticancer agents therapy, or radiation therapy as we reported, showed relatively small or minute increase in toxicity of these cytotoxic treatments.
Insights
Tumor growth and metastasis rely on angiogenesis. Researchers are developing anti-angiogenic agents, with many showing promise in clinical trials and combination therapies with minimal toxicity.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Context:
- Angiogenesis is crucial for tumor growth and metastasis.
- Tumor-host interactions play a role in angiogenesis and anti-angiogenesis.
- Numerous anti-angiogenic agents are under investigation for cancer treatment.
Purpose:
- To review current anti-angiogenic agents and their therapeutic potential.
- To highlight ongoing research in inhibiting tumor angiogenesis.
- To assess the safety and efficacy of combination therapies.
Summary:
- Several anti-angiogenic agents like Marimastat and VEGF/R inhibitors are in clinical trials.
- Ongoing research focuses on MMP inhibitors, Endostatin, and COX-2 inhibitors.
- Combination treatments with conventional therapies show limited toxicity increases.
Impact:
- Provides an overview of anti-angiogenesis strategies in cancer therapy.
- Highlights the potential of novel therapeutic agents.
- Informs future research directions in tumor angiogenesis inhibition.